PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, ...
(WorldNews Business)

SOUTH PLAINFIELD, N.J., May 20, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical research by the rare genetic disorders community. This year`s funding will accelerate innovative research projects to improve Duchenne muscular dystrophy screening in infants and support earlier diagnosis of this progressive, muscle-wasting disease. `We were overwhelmed to receive so many outstanding applications in the first year of PRIORITY and to see such a breadth of ideas to improve the screening and diagnosis of Duchenne,` said Dr. Claudio Santos, Senior Vice President, Global Medical...